DOUGLAS WILLIAM BONHAUS
Pilots at Via Sarasan, Encinitas, CA
License number
California A0178751
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
251 Via Sarasan, Encinitas, CA 92024
Professional information
Androgen Receptor Modulators And Methods Of Treating Disease Using The Same
US Patent:
2007000, Jan 4, 2007
Filed:
Feb 6, 2006
Appl. No.:
11/348949
Inventors:
Nathalie Schlienger - Frederiksberg, DK
Jan Pawlas - Frederiksberg, DK
Alma Fejzic - Frederiksberg, DK
Roger Olsson - Bunkeflostrand, SE
Birgitte Lund - Bagsvaerd, DK
Fabrizio Badalassi - Copenhagen K, DK
Rasmus Lewinsky - Hertev, DK
Mikkel Thygesen - Copenhagen O, DK
Douglas Bonhaus - Encinitas CA, US
Jan Pawlas - Frederiksberg, DK
Alma Fejzic - Frederiksberg, DK
Roger Olsson - Bunkeflostrand, SE
Birgitte Lund - Bagsvaerd, DK
Fabrizio Badalassi - Copenhagen K, DK
Rasmus Lewinsky - Hertev, DK
Mikkel Thygesen - Copenhagen O, DK
Douglas Bonhaus - Encinitas CA, US
International Classification:
A61K 31/675, A61K 31/54, A61K 31/5375, A61K 31/445, A61K 31/40, A61K 31/495
US Classification:
514079000, 514227500, 514237500, 514255030, 514319000, 514408000, 544059000, 544392000, 544157000, 544162000, 546022000, 546205000, 548577000
Abstract:
Disclosed herein are bicycloaryl compounds of Formula (I) that selectively modulate nuclear receptors, preferably the androgen receptor, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and methods of treating disease comprising administering a compound of Formula (I) to a patient in need thereof.
Compositions And Methods For Treating Cognitive Disorders
US Patent:
2006006, Mar 30, 2006
Filed:
Nov 14, 2005
Appl. No.:
11/241316
Inventors:
Douglas Bonhaus - Encinitas CA, US
Renee Martin - Sunnyvale CA, US
Renee Martin - Sunnyvale CA, US
International Classification:
A61K 31/538, A61K 31/517, A61K 31/18
US Classification:
514230500, 514252170, 514256000, 514254060, 514602000
Abstract:
Methods and pharmaceutical compositions relating to selective antagonists of the 5-HT6 receptor and 5-HT2A receptor useful for the treatment of cognitive disorders are presented.